CDXC - Earnings call transcript Q3 2024

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Thanks for standing by. My name is Mandeep, and I'll be your operator today. At this time, I'd like to welcome everyone to the ChromaDex Third Quarter 2024 Earnings Conference Call. [Operator Instructions] I would now like to turn the call over to Ben Samson. Investor Relations.

begin. may You

Ben Shamsian

Ozan afternoon, Dr. of Good are to Corporation's for Affairs, Financial ChromaDex Chief of Vice Thank and Q&A. will Scientific Results and join Investor Quarter Regulatory Officer, Chief Fried; XXXX Officer, Andrew today and Call. Third Senior Executive President Shao. you. Dr. Rob welcome Pamir; Shao With ChromaDex's call us the

and of and anticipated sales cash the the business needs, and future statements of call and results opportunities and in related results, statements development to the clinical performance, new may trial and and research regulatory conference investor interest operations. such plans of Today's markets, of including NIAGEN development timing products of operating business results trials, expansion financial as opportunities, well include future prospects ingredients ChromaDex's as timing forward-looking the filings,

as are results. matters call Forward-looking to statements. give the this and have anticipated statements statements differ represent that only assurance conference subject uncertainties. and the estimates materially risks on of relate not to intended forward-looking results cause date are the activities statements to factors the actual these and could company's any from activities not Because to Many ChromaDex's forward-looking to inherently in actual yet occurred, or results future

the or well filed in as conference factors call risk statements flows expectations. SEC, assumes forward-looking business. the with Please with this including on recently global on the to include after condition, that our date no update results economic most cash conditions obligation conform results These its those operations, XX-Q contained report of to actual statements, in market forward-looking quarterly Form of financial company and ChromaDex's the as changes note to any

this reconciliations the the release, are measures. non-GAAP earnings appropriate website, In present this call addition, measures. were earnings company's and to which company's financial and available presented financial on press presentation The references issued in information certain afternoon GAAP

conference Relations this call via is www.chromadex.com. webcast. the will recorded of Investor The website section being at webcast at Finally, our be available

With call Fried. turn the that, to Executive now it's my our pleasure Officer, Chief to Rob over

Robert Fried

Ben, share revenue, quite the I we on year-over-year you in investor a thank third increase afternoon, to with achieved am line in pleased income $X.X of call. line today's both and you, XX% I that record and Thank quarter, for top good $XX.X our our bottom and net everyone. million million. results joining

ended $X.X in marks $X.X positive no and also of This our EBITDA, reaching cash we flow of million. adjusted the quarter We quarter sixth with million, debt. quarter $XX.X total positive consecutive million and generated cash

highlight which record The This growth NIAGEN primarily and to clinics maintaining ingredient growth quarter, at this NIAGEN+ dedication fiscal quarter's or quarter, sales our sales profitable a debuting year-over-year. pharmaceutical while financial achieving third advancing as $XX.X well business, business of selected e-commerce our in discipline IV for the as the initial our million growth included grade XX% representing NIAGEN NIAGEN were key results still by this and to business quarter our unyielding driven initiatives.

as following quarter, website. to E-commerce efforts as Amazon Prime July. was a we trends growth supplement. boosting TRU top be marketing our sustained reinforce as On the continues with contrast stable saw own growth well was the fueled refreshed our In growth Amazon, position by of the stronger on Day quarter second This NAD in where to NIAGEN's cornerstone reflected third business. total year-over-year, e-commerce

least. media better of engage content to address marketing website, effectively Amazon and say PR live offered influencer refreshed social the through awareness promoted to as we conversion were marketing. messaging our marketing brand customers our NAD up taken well from as improve efforts products brands and emergence had own improvements to claims drive through to to encouraged competitive to to On Additionally, seeing through boosting we steps not see that the that and that are performance did better with their

More updated take along platform recently, research. our the advancements with on completed of website as product of a redesign excellence XX consumer as refreshed the migration the in and our well web commitment own a with to educating has of an years team the to company's scientific NAD company's innovation

gold As and we NAD scientific in continue to in standard industry. the superiority represent professional the

influencer marketing efforts and retention to well will focus as as product optimizing to and and continue through optimizing strategy drive media Our on marketing brand customer value. awareness conversion social long-term

revenue during occasional an an retail experiencing to overall Watson valued remained steady time unfortunate customers a partner providing with Watsons sell-through where have quarterly market is direct decline. fluctuations. strategic the Kong recurring year-over-year remains steady Hong

and including this KOL are third initiatives impact messaging, on have promote our the on testimonials different with messaging and better year-over-year the customer decline personalized in social may an impact collaborating YouTube newly retain and year and marketing customers. media them year, leveraging acquired we close actively new and While and year, on to quarter the Watsons into sales utilize to had consumer to acquisition full to sales with an for next the

to Since This the our and date. expanded the NIAGEN+ of clinics then, consumer of weeks. and to that we shipped to Wells through launched NIAGEN greatly line, weeks, NAD now the we at few The launch expecting next is clinics Pharmacy XXX NIAGEN+ XXX quarter, supplementation just reach we in in In IV product the availability have expand over awareness of growing. the expect injections introducing indicates select have network. to over coming benefits clinics NIAGEN+ be rapidly

Kendall article is benefits. was NAD to Jennifer therapies the IV health-conscious trends much New seen as and NAD GLP-X. like celebrities such that Jenner in The other Hailey for areas celebrities such Bieber, Post we've and consumers, recent Aniston, highlighted also amongst longevity York turning gaining that are reported in traction There as article a supplementation

NIAGEN shorter times NAD comfort enhanced spotlighted Magazine IV resulting in higher than IV therapies. recently and Forbes NAD traditional Drip particular, NAD treatment boosting premier Another a publication in session released offering levels as last to week

a will advance to set standard that name. a As space, a our IV NAD become are household NIAGEN will NAD IV new leader the for we goal and in in NIAGEN therapy confident

drug calls, and the for telangiectasia, drug disease shared effort use for initiated U.S. communication the company's treatment now as had riboside and of application AT. In as investigational earnings a ChromaDex meetings the or part NR nicotinamide ataxia orphan IND rare that prior pediatric the for of In in FDA of I designation FDA designation with granted pursue is candidate to organize September, treatment working to new an the of AT.

the study, which updates still will around half Additionally, the we of first be year. completed expect to last discussed NO-PARK quarter, within I next

dialogue are the updates is University investigators the the there detail near While Auckland much sharing progress go of forward process. in future important this we from through to in Hospital consistent not look to as the more we are we on publicly, Parkinson's We share with study. allowed

for years Ozan many As steady we our are like with resuming many this as of you transition. know, a to Officer. is been new We're James our Controller, who leadership Pamir his this operations excited and proud as and during managing September, to first him for very Financial of has come. Chief that I'd many, period that during in be in controller impressive ChromaDex's to thank role financial working announced appointed James Lee,

we our has acknowledge done to strategy Yu, our to like also in exceptional members am helping team proud to rise VP an X, during also we finance departments It and of manage transition to at have occasion. see period. beat, our job testament would Finance, exceptional I the and talent Between did especially who Wesley quite a is ChromaDex. us a not I the this miss the to

company's enhancing With years XXX to hear Life traded as Chief funding from ChromaDex rounds. growth strengthening very look on for responsibility Ozan introduce spearhead him reinforcing brings pharma you in expansion listing forward insights am through well NASDAQ impact multiple business operations efforts will to valuable instrumental the Relations. leading to a biotech shortly. for experience, Now firm. would I pivotal Sciences, X in and this discipline, phase the by at our I Financial he our excited who space organization. I have profitable positive capabilities over take with to our overseeing financial Investor expertise. his be as like our will including much guiding and Ozan publicly for as of will Ozan, Officer internal the the

sustainable years. To for growth date, we've as significant profitable we progress made saying towards been have several

We as our innovation well. advancements have continued in pipeline

of and grateful years I'm on NAD how innovation pioneering celebrates ChromaDex have we research come. XX far to As reflect

in I'm we've confident strong building XXXX. the moment accelerated in Looking the toward established and foundation growth ahead,

science to NAD we believe an positioned a we authority industry NIAGEN the household for well are of yet global to of as I While provide as NAD outlook not are very a paragon the ready XXXX, name. make and

to to Ozan? quarter's now And I closing like Ozan more to detail run call remarks. would over through to the financials and hand then Q&A on and in the

Ozan Pamir

is have Thank who joined team It today. to be pleasure partners you, to and members Rob. introduced investors, our a

life my are I've my mentioned, was a last science we listed banking because as a Rob unparalleled the I X by career As the opportunities where spent investment of on the have. career sciences that of NASDAQ of biotech focus in years following ChromaDex the joined provided companies. CFO company

significant pharmaceutical the its growth, stable core and are is the at a point with ChromaDex company a opportunity lead the verticals. help The we for sector. expand the to plans of market potential excited to by through the next through into phase inflection growth where I'm presented strategic a of pursuit new unique business foundation provides in

efforts. as My and on shareholders to the points new company long-term place and move to to business advance community through the will discipline relationships with strengthen be focused our Relations discipline the value investment pursue our operations strengthening objective and My leverage entry be chapter. the also ensure to addition my strategic in company's position already in focus the into across we is operations and promising forward on immediate this to for experience expertise to Investor the fiscal I company's strengthening financial and look sustainable will evaluate pharmaceutical helping as financial CFO optimizing the in company's industry.

month, with requirements. to we stepped independence as auditor comply last announced merger following As with Marcum our CBIZ, down LLP's Marcum

facilitate the their them for suitable as years, the thank the ChromaDex last phase ChromaDex. appointment of new that of is audit of growth one for to we first be in of will my a initiatives next While at firm CFO XX-plus services

and with I has objectives, the Rob a highlighted the been success, and to strong operational ChromaDex, upholding ChromaDex's seen discipline momentum. financial in these which are I committed its to have continue recent quarter. this and foundational have ChromaDex I'm place to agree team leadership that that most key Beyond by at encouraged believe I'm efficiency in

net Total XX% increase of in performance. moving XXX% financial This growth $XX.X or million, $X.X of the a third were sales third a quarter quarter Now the our to significant to on third quarter XXXX XXXX. sales select clinics. million was compared $X.X to our primarily in or increase to key million pharma-grade $X.X driven sales NIAGEN with in of million NIAGEN initial an NIAGEN food-grade ingredient higher impressive and sales of partners by

NIAGEN BXB sales. XX% Additionally, by in sales sales the offset $X.X grew Watsons a million decline partially growth as other by were in TRU e-commerce and

improved benefits NIAGEN and XX.X%, higher XXX mix, of in from in our utilization points third driven deferred pharmaceutical-grade of by including margins gross increase XX.X% basis with labor the improvements Our and This to rates the XXXX. launch changes sales. overhead quarter revenue compared up in recognition was the of and to product

Research operational in efficiency scale development new demonstrate ongoing and strategically as continue year-over-year in to returns. marketing stable a NAD management. remained net as XX% to sales selling investments This advancing expenses while sales the reflects We improved the our development compared strong of marketing and of focus to and cost quarter XXXX. to of XX.X% achieving and investing and on we efforts percentage The continue precursors. to third innovations expenses higher

to launch litigation. administrative year expenses to increased higher defense and our IV and NIAGEN+ expenses previous NIAGEN General $X.X million support legal the compared patent by or due to

The which the the third a attributable per of improvements third the XXXX, loss our For for versus by third $X net million sales to of million XXXX, of of loss and $X.X gross a stockholders expenses. is million, higher to for income loss was $X.X million quarter driven of partially an share, net in income by increased improvement XXXX compared of offset quarter and and common $X.XX operating $X.X net per third operating improvement million of net XXXX. $X.X quarter the income of $X.XX the or meaningful was quarter share margin

the Moving flow. balance and cash on to sheet

cash in strengthen. no and ended to $XX.X with continues quarter sheet balance Our the We debt. million

For million the working accounts last trade X in largely capital accrued in a was offset in credit in partially the cash improvement same was months year-over-year $X.X with year. The by driven and ended expenses increase lower changes by million reduction $X.X a September compared in payable XX, by provided difference relatively provisions period a operations million receivables, greater XXXX, net losses, net for greater and income. $X.X to

As business, IV. to we top new updated our press outlook NIAGEN key XXXX range line. accompanying from partnerships by At metrics our is outlook, sales this outlook in the growth year, net for year-over-year the adjustment our growth earnings year-over-year existing launch it by At P&L realized in financial approximately presentation. XX% expectations the a relates XX% represents our driven detailed growth. and year found point time, Previously, upside release this and our This to included growth. of be e-commerce on to information slide full to expect global can and our only XX%

remain Beyond outlook. our key quarter's last these with adjustments, metrics consistent

during We maintaining similar fourth gross We the IV steady initiatives. make and in plan strong and expect slight to to while year's marketing development and quarter sales the investments strategic our to increase continue prior support efficiencies margins investments to over to core support improvement launch, XX.X%. the NIAGEN research and a with

healthy a operating here exceptional core flows generating ChromaDex will thus be our grateful impact to advancements towards for am and our build plans. this quarter a positive opportunity sheet. year-to-date, investors. and to upon our continue making positive discipline customers, focus the cash look solid, forward In encouraged continued our and organization and growth, continue far confident balance we making that in supporting shareholders the and a to at our business this success I summary, I'm in performance greater I partners, to remains financial for leader ChromaDex's by strategic business I'm and the

Operator, we are now to questions. take ready

Operator

line & [Operator with Cohen Jeff Instructions] of Our Thalmann first question comes from Ladenburg the Co.

Jeffrey Cohen

noise. Rob, the background sorry for

what So about injectable. could available? little the Could bit clinics -- and the and heard through up perhaps And formulations now, XXX SKUs was I you talk out dosages XXX are both shortly. you walk a IV us the there XXX or now, to now at that

Robert Fried

beyond they XX ingest people the X it for third if milligrams. Right. that an it It's is it very -- beyond the XXX continue today, far, major third we in factor, be to was going in to continue to them the within probably factor expect quarter. the in are are clinics generally of to quarter, grow opposed few XX and into in expect IV for we major NIAGEN to in to Most getting who and The hours NAD units it and about that. to so expect It's next to interest a the clinics NIAGEN+ XXX and we XXX were X performance weeks, in getting IV. taking as the -- quarter strong the

people offer cases, milligrams, at getting, milligrams. in SKU also although Jeff? are getting XXX XX and an and are popular. are who growing they would rate, growing it, injection in both also We I say, growing, most get quite are get more I going a could Did injection the shots but is and rapid The the

Jeffrey Cohen

for perfect. it And you. I I was one's guess welcome slip this if and Ozan could that just just and in more, Yes, one

to what million Could You the then the the then heard was? just X talked I quarter. and you about you And and about this $X.X cash you then some I months, something that production for And spoke for clarify else. credit. followed the $X.X payables down million

Ozan Pamir

you numbers me remind you heard? like Can which

Jeffrey Cohen

You're you... walking through

Ozan Pamir

heard, I guess, You right? just

Jeffrey Cohen

What the that? was million The the for quarter. $X.X and payables

Ozan Pamir

we million. improvement the the net $X.X just in was had the income, That

had provision And receivables, So an income. was for the the last we in credit we -- through in and $X.X trade provided improvement was had so million cash had lower operations net was million, kind losses. all and I in $X.X by million we increase -- reduction accrued a $X.X the offset difference. talking by payable was we accounts that a of that breakdown year, had And of expenses,

Jeffrey Cohen

for more, proceed how And could then talk AT through does may you Okay. me. Perfect. it and XXXX? one that about That Rob,

Robert Fried

Jeff? Can you again, ask it

Jeffrey Cohen

may Can this indication the to balance we and you what or talk and about orphan year look during XXXX? ataxia of the see forward

Robert Fried

and to on we've get FDA. the our conversations they'll be We're hope submission to minimal, are application. their notes be been don't the study pre-IND having their pursue -- having what in We And get notes the and XXXX. know until on moving able with on our then, Hopefully, then a month. we we'll IND within really

Operator

Selvaraju from with the of comes Wainwright. line question H.C. Raghuram next Our

Eduardo Martinez-Montes

of This wanted of to in the sales? the is pricing for BXB Raghuram. the NIAGEN. that one curious And behalf Eduardo like e-commerce what's which a on dose NIAGEN included specifically single were segment or sales I section in was clarify calling for I the of

Robert Fried

to asking. want just the question I IV? Eduardo, Are about asking clear the you be you're about

Eduardo Martinez-Montes

Correct. plus. IV and the

Robert Fried

Okay.

product, what as we NIAGEN are The at product of the to products clinics. all X the NIAGEN generally milligrams. So these well kit, refer is we as IV XXX test NIAGEN+ available IV injection NIAGEN -- as the is NAD

level What offered session. up milligrams sends the generally to that they compounding the partner $XXX XXX-milligram pricing in pharmacy charging clinic between they are and vials, we've $XXX and Our clinic. doses, is are observed is XXX in and the of then at per that

Eduardo Martinez-Montes

NIAGEN+? current reported That's category the sales helpful. what really you now, And Okay. in the that were were

Robert Fried

grade. and are sales as pharmaceutical under Those they're ingredient listed

Eduardo Martinez-Montes

And got see the grade How improvements. potential just there. edge, you it. do pharmaceutical it. Got follow-up Okay, one other

XXXX? through had margins great you likelihood improvements already. further in the of guys see the You Do growing improvement a that or

Robert Fried

referring they -- depending So fluctuate of these that, the on mix think revenue. are these I margins gross you're to margins,

We've gross of higher the has overall. than have that new segments higher company NIAGEN+ gross others. margins our business certain initiative than margins the indicated So

So physical and margins. think sales has as on retail that generally NIAGEN+ downward margins. gross impact generally that gross have retail But will positive ingredient we grows, the a any NIAGEN on pressure

So it's we future that margins the now. see in around gross right being range for the foreseeable

Operator

Tieton comes Dezellem with question of Management. next Our the Capital from Bill line

William Dezellem

Congratulations on the a you you a nice on governor number clinics, What biggest in? clinics of when is what quarter. -- are or the that restraint growing at the look

Robert Fried

there X,XXX the clinics We think in are that United approximately States.

of hydration clinics. Some IV are those

NIAGEN+ that of a could are many anti-aging of them clinics. different Some wellness beauty are clinics, offer There clinics theoretically clinics, types product.

So there's go market for out quite lot of a there to after. us addressable

restraint, terms real is have we point at of the restraint this only In of supply material.

William Dezellem

And basically be that on to shoulders would Grace's out make more?

Robert Fried

to but ingredients really a the highly conservative highly, are the more, we us no. you've Actually, take We as you've source difficult the but from sterilization while, and get pharmaceutical, It's But that years processes pharmaceutical-grade and within NIAGEN. a and testing in time It's do, a a with Grace. to years since with go completely it pharmaceutical We to the ingredient. take to especially we to and coming And doing taken quality the approved. to source from probably months, able don't there'll been know we to amount we've it our It's different in deliver make it manufacturer. expect a controls, be be come it. with really grade But whatever weeks us through FDA been and our different make. -- already while does a products we fair product. a been we think a this different we And over for ChromaDex much of in -- it's place.

William Dezellem

have to the number how they are NIAGEN from at then early responding be NAD do from to And -- Great. from clinics, be receiving the two, to you they concept? they look number that new one? the as response Or truly tend And the are tend IV? new been the to converts patients doses the to

Robert Fried

a That's good question.

only been of in now we've the months. market a So for couple

one in of been NAD are from because These they're used to majority none NIAGEN the used IV, every absolutely hours So used far are who of NAD NIAGEN stomach which pains are of NAD an to thus sweats with higher much to ecstatic serious for have levels with of They're and resultant infusion. get going the NAD. And converted the happens course, them people and and headaches, infusion. very IV. are taking to the consumers

used extremely they're to. So to relative they're experience an having positive what

initiative, around in last largely lately, is But in the of a this and because general. press been great there's months, the several of deal NAD IV NIAGEN

in So great curiosity there's NAD. a marketplace the of about deal and NIAGEN

into the months So to our we NIAGEN it's increase seeing endeavoring are out try early, number only experience a NIAGEN shot. a and that's going an consumers there these But been but in we've clinics again, of or X IV thus far. new

William Dezellem

have in and a due relationships you've And in the XXXX, simply had for helpful. to correct would to a it That's benefit you'll if full higher of the supposition that 'XX this small that the brought be directional on a growth only that that or should clinics year? year's portion secondarily, a get relative than to may, be growth I from IV 'XX in new compared will 'XX you year full

Robert Fried

just still the the market assessing demand. We're and

it's said, X only months I out there. As been

yet of for not XXXX. too for understand us behind we're say. early forecast it's kind the but your to So thinking, I any providing logic

William Dezellem

give I opportunity an thought anyhow. I'd you

Operator

with MKM comes Partners. of question next ROTH the Sean line Our from McGowan

Sean McGowan

question that My now Ozan, clarification phone, for meet on grade to person. you NIAGEN the you really in on as food-grade to first meeting some opposed before provide you NIAGEN and is product. pharmaceutical by Nice asking breakdown consumer

that. growth that the major I in the But according contributing think where like that quarter XX-Q, the of only Rob, the lot, it said like $XXX,XXX incremental you the looks providing grade. factor to revenue food-grade to a is lot more -- pharma that's a up NIAGEN than the was

the the that's something related food-grade there is pharmaceutical? to in So NIAGEN

Robert Fried

the view getting it a in vertical business than and we and biohackers, are people is have the or getting new Many have just the large really, we P&L see over to our influencers. IV NIAGEN+ vertical, IV more had or year, press or I NIAGEN over People people as we also NIAGEN new is product the as said who talk social and premier have followings a strategy. NIAGEN+ this switching that celebrities last, vertical, that to are gradually we're IV or So of NIAGEN are the podcasts. IV on as media NAD who -- marketing athletes

we that marketing see halo but strategic has effect that initiative a business already a So a on NIAGEN NIAGEN. only not out. as And TRU we're play IV seeing

I of sales meant one is the our that what the e-commerce because why that increasing we're So by was attention is of reasons business main in getting via NIAGEN IV.

Sean McGowan

that. the Okay. Nestle is And is makes That of or food-grade million I that get Is sense. $X.X the product? then up that actual to NIAGEN or unrelated line something. consumer like something

Robert Fried

supply initiated So to quarters, one as certain NIAGEN customers them. a of a our contributing food-grade selling an in their awareness NAD Amazon previous us, are healthy continue and are Amazon of in to and and for to year, places ingredients cannibalizing business But and general, NIAGEN that they're extent, why other other excellent. sales sales and it's so It partners, is strategy to and on NIAGEN ingredient in earlier they are business up. with we said sales combination but good the in they're we our is

Sean McGowan

Okay.

on compare to more. sense. NIAGEN+ the could NIAGEN makes TRU then the form milligrams the body? just talk are impact that in When milligrams, at that the That you XXX about And would capsules how dosage in terms the dosages in one XXX of Okay. on

Robert Fried

still long-term -- the are what the scientists few differential Well, is. months studying a our over Right.

pharmaceutical-grade goes have NR you before a up pure data gets cells comparison. effective. is I organs one have it NIAGEN, bloodstream, proven times in see comparing therapeutic bloodstream on liver, that and NIAGEN we give NAD of to to published small to the the quarter put going seen share and it it you levels potency . But you barrier amount of TRU relatively that that I'm pure And when not you don't we a it into But capsules. within the blood-brain directly studies X crosses that sterilized IV benefits. goes into study So on And from to many the IV the into which and prophylactic dose. there high But to the out has has through we've get when we've capsules, extremely all wait data yet the the swallow taken and the the hours the understand NAD gut NIAGEN delivers IV to that then in NIAGEN published comparing and we NIAGEN and of into have it gets IV. of bloodstream, is the what

Sean McGowan

able that data? And when the NIAGEN+ to that have do marketing part a will of you be you of make

Robert Fried

intend We to.

Operator

the JP Our next line question comes Farmhouse of from with Mark Equity Research.

Jan Mark

market expanded how there? the it's how think some it -- roughly great is? you at do that was to are XXX but congratulations, alone know of nice in Rob, out think Ozan, looking availability clinic in at. numbers sort addressable I you to quarter. total I to the talked do XX,XXX, about to have it no maybe clinics wellness press many U.S. clinics say idea, Is the One I question so far welcome a area. But are about And XX,XXX, large market like would you. also, meet your quick I you in release,

Robert Fried

market that clinics We estimate for around deliver the to IV addressable be X,XXX.

Jan Mark

Okay.

And that do that X,XXX countries?. actually -- you or right? kind then obviously we So alone. work. clinics other of at of U.S. the do look it, of outside other There markets that's a won't not, that are lot that's

Robert Fried

finished? are getting many sorry, you I'm -- phone Are calls many, ahead. go We

Jan Mark

Yes.

Robert Fried

sorry, I'm ahead. go

Jan Mark

that... sure anything. say didn't not whether I'm I

Robert Fried

something. hearing I'm

interest, of is bit We of are the great of a interest quite deal -- outside there a U.S.

into we regulatory and We are approved are appropriately. following it and when we doing safely border navigating making our way do we transfer through across do everything regulatory making approvals is sure as countries, sure rules we and that the and those

before it emerge other take little we countries NIAGEN+. a So may in time with

Operator

like That closing turn remarks. for concludes I call today's the to Yu Wesley to now session. would Q&A over

Wesley Yu

your you, continued Mandeep. you, XXXXXXX. X:XX replay replay is Thank for replay support There Thank this joining X-XXX-XXX-XXXX The ChromaDex. of p.m. be us of call is the today. number today for everyone, a and Time ID will and beginning at Eastern

Operator

This today's call. concludes

You disconnect. now may

ChromaDex (CDXC) 31 Oct 242024 Q3 Earnings call transcript